NCT01822886View on ClinicalTrials.gov

Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

July 31, 2018

Conditions
Peripheral T-cell Lymphoma
Interventions
DRUG

Romidepsin + Gemcitabine

Romidepsin 12 mg/m2 day 1,8, 15 + Gemcitabine 800 mg/m2 day 1, 15 for 6 cycles by 28 days followed by Romidepsin 14 mg/m2 day 1, 15 to PD

Trial Locations (4)

10126

A.O. Universitaria Citta' Della Salute E Della Scienza Di Torino, Torino

15121

A.O. SS. Antonio e Biagio e C. Arrigo, Alessandria

20133

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

40138

Istituto di Ematologia ed Oncologia Medica A. Seragnoli Policlinico S. Orsola, Bologna

All Listed Sponsors
lead

Fondazione Italiana Linfomi - ETS

OTHER

NCT01822886 - Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients | Biotech Hunter | Biotech Hunter